Merus (NASDAQ:MRUS) Receives $85.31 Consensus PT from Brokerages

Shares of Merus (NASDAQ:MRUS) have received an average recommendation of “Buy” from the sixteen analysts that are currently covering the firm, Marketbeat Ratings reports. Fourteen investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $85.31.

Several equities research analysts have recently weighed in on MRUS shares. The Goldman Sachs Group started coverage on Merus in a research note on Thursday, November 21st. They set a “buy” rating and a $73.00 price objective for the company. William Blair reissued an “outperform” rating on shares of Merus in a research note on Friday, February 28th. Piper Sandler initiated coverage on Merus in a research note on Thursday, February 13th. They set an “overweight” rating and a $84.00 price objective for the company. Guggenheim reaffirmed a “buy” rating on shares of Merus in a research report on Wednesday, February 12th. Finally, Bank of America decreased their target price on Merus from $73.00 to $70.00 and set a “buy” rating for the company in a research report on Monday, March 10th.

Merus Price Performance

Shares of MRUS stock opened at $47.22 on Thursday. Merus has a 12-month low of $37.77 and a 12-month high of $61.61. The firm has a market capitalization of $3.26 billion, a price-to-earnings ratio of -11.95 and a beta of 1.15. The business has a 50 day simple moving average of $42.99 and a 200 day simple moving average of $46.28.

Merus (NASDAQ:MRUS) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The firm had revenue of $9.14 million for the quarter, compared to analysts’ expectations of $10.57 million. On average, equities analysts anticipate that Merus will post -3.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Merus

Institutional investors have recently bought and sold shares of the stock. State of Wyoming bought a new position in Merus during the fourth quarter valued at about $48,000. Wells Fargo & Company MN increased its stake in shares of Merus by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 300 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Merus in the fourth quarter worth about $60,000. Avior Wealth Management LLC bought a new position in shares of Merus in the fourth quarter worth about $76,000. Finally, Lazard Asset Management LLC bought a new position in shares of Merus in the fourth quarter worth about $84,000. 96.14% of the stock is currently owned by institutional investors.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.